BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) to Release Q3 2023 Financial Results on Nov 20, 2023; CEO to Host Conference Call at 10:00 a.m. EST

- Management to Hold Conference Call at 10:00 a.m. EST -

TEL AVIV, Israel, Nov. 13, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open.

The Company will host a conference call at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 22, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.

Contacts:

United States
John Lacey
BioLineRx
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2023-results-on-november-20-2023-301985329.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx Ltd. release its unaudited financial results for the quarter ended September 30, 2023?

BioLineRx Ltd. will release its unaudited financial results on Monday, November 20, 2023, before the U.S. markets open.

What time will the conference call be held?

The conference call will be held at 10:00 a.m. EST.

Who will be giving remarks during the conference call?

Philip Serlin, Chief Executive Officer of BioLineRx Ltd., will be giving remarks during the conference call.

How can I access the conference call?

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website.

Until when will the call replay be available?

The call replay will be available until November 22, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.